While NT-proBNP is a widely used biomarker for HF diagnosis and prognosis, MyBP-C and hs-TnI may offer additional diagnostic value, particularly in identifying patients with AMI within the HF population. This evidence concerns the gene NPPB and hydrops fetalis.